Abstract: Dabigatran is a novel antithrombin anticoagulant that was approved by the FDA in 2010 to be used for the prevention of stroke and venous embolism in patients with chronic atrial fibrillation. In this article, we present a case of a 74-year-old Caucasian female who presented to the Emergency Department with acute lower GI bleeding and acute metabolic encephalopathy. The patient INR was 15.4, besides other labs abnormalities. The patient was found to have an acute live injury and acute renal failure that was believed to be induced by the recent start of Dabigatran to treat he Atrial fibrillation (AF). Patient condition improved with stopping the Dabigatran (Pradaxa) immediately, administering FFP, and Hemodialysis.
[1]. Friedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., et al. (2010). Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thrombosis research, 126(3), 175-182.
[2]. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361(12), 1139-1151.
[3]. Rochwerg, B., Xenodemetropoulos, T., Crowther, M., & Spyropoulos, A. (2012). Dabigatran-Induced Acute Hepatitis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 18(5), 549-50.